Divergent Standard Care Makes Full EU Regulator/HTA Harmony Unlikely
This article was originally published in The Pink Sheet Daily
While EU regulators and HTA bodies are coming together on major drug development criteria, differing standard care regimes across the 28 European Union member states makes real harmonization seem far off.
You may also be interested in...
EFPIA is calling on its members to sign up to the European Commission’s multi HTA early dialogue initiative to harmonize some significant aspects of European reimbursement.
MHRA’s Beneficial EU Relationship And Profitable Synergies With NICE: An Interview With Michael Rawlins
In December, Michael Rawlins was appointed head of the U.K.’s Medicines and Healthcare products Regulatory Agency. He recognizes the MHRA’s mutually beneficial relationship with European counterparts and is looking to safeguard synergies with other national regulatory bodies and NICE.
The EMA has recommended suspension of some 700 drug formations linked with Indian clinical trials company GVK Biosciences, but assures national agencies that this won’t result in shortages or safety issues.